相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

基于DR5特异性TRAIL变体的新型融合蛋白,具有增强的抗瘤特性

Anne V Yagolovich¹, Alina A Isakova^1,2, Ekaterina V Kukovyakina²

¹Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.

Biochemistry. Biokhimiia

|October 9, 2025

概括

一种新型的融合蛋白,SRH-DR5-B-p48,通过诱导亡和抑制血管生成,增强了癌症治疗. 这种多目标药物在治疗各种固体瘤方面表现有前途.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物技术是生物技术.

背景情况:

与瘤亡因子相关的诱导亡的配体 (TRAIL) 选择性地诱导癌细胞中的亡.
第一代TRAIL激动剂的临床抗瘤活性有限.
向瘤细胞和瘤微环境对于提高疗效至关重要.

研究的目的:

开发一种多目标重组聚变蛋白,SRH-DR5-B-p48,用于增强癌症治疗.
通过DR5同时诱导细胞亡,并通过向VEGFR2和FGFR1.1来抑制血管生成.
在临床前癌症模型中评估SRH-DR5-B-p48的疗效.

主要方法:

设计和生产了SRH-DR5-B-p48融合蛋白.
利用分子动力学来分析受体相互作用.
使用酶相关的免疫吸收试验 (ELISA) 来评估结合 afinities.
在3D细胞模型中评估了细胞毒性和抗血管性作用.

主要成果:

SRH-DR5-B-p48对DR5,VEGFR2和FGFR1.1具有很高的亲和力.
与DR5-B.相比,融合蛋白证明了瘤细胞杀伤的增强.
SRH-DR5-B-p48有效地破坏了类似瘤的结构,并抑制了纤维细胞的增殖.
分子动力学表明和DR5-B域之间存在非特异性相互作用.

结论:

SRH-DR5-B-p48是一种强大的多目标药物,用于癌症治疗.
融合蛋白有效地准瘤细胞并抑制血管生成.
SRH-DR5-B-p48显示出治疗固体瘤的巨大潜力.

关键词:

在DR5中,DR5是DR5.在DR5-B中,它是DR5-B.一个FGFR1.轨道的轨道是一个轨道.在VEGFR2的基础上,VEGFR2 聚变蛋白质的融合蛋白质瘤治疗的治疗方法

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...